AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amylyx Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$27.33+0.99 (+3.76%)
Close on Oct 19, 2026
- Market cap
- $3.04B
- P/E (TTM)
- –
- Dividend yield
- –
Amylyx Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Amylyx Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $3.05B | $197.05M |
| Enterprise Value | $2.79B | $106.56M |
| PB Ratio | 12.73 | 2.14 |
| P/TBV Ratio | 12.73 | 2.46 |
Income (trailing twelve months)
| Measure | Amylyx Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$162.10M | -$21.44M |
| Net Income | -$152.09M | -$22.46M |
| EBITDA | -$162.10M | -$16.91M |
| EPS (Diluted) | -$1.43 | -$0.83 |
Returns
| Measure | Amylyx Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -74.7% | -53.1% |
| Return on Assets (ROA) | -66.2% | -41.0% |
| Return on Capital Employed (ROCE) | -66.6% | -37.8% |
Balance sheet
| Measure | Amylyx Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $250.76M | $62.42M |
| Net Cash (Debt) | $250.76M | $15.68M |
| Net Cash Per Share | $2.25 | $0.65 |
| Equity (Book Value) | $239.17M | $48.79M |
| Book Value Per Share | $2.15 | $1.36 |
| Tangible Book Value | $239.17M | $23.06M |
| Working Capital | $235.19M | $75.77M |
Financial position
| Measure | Amylyx Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 12.12 | 3.30 |
| Quick Ratio | 11.86 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Amylyx Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$126.58M | -$12.35M |
Efficiency
| Measure | Amylyx Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | -$1.12M | -$732.08K |
| Employee Count | 136 | 73 |
Dividends and yields
| Measure | Amylyx Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -4.99% | -21.2% |
Shares
| Measure | Amylyx Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 111,423,000 | 59,128,900 |
| Shares Change (YoY) | 36.5% | 11.1% |
| Shares Change (QoQ) | 0.31% | 0.54% |
| Float | 102,443,000 | 48,744,500 |
| Shares Held by Insiders | 8.06% | 11.8% |
| Shares Held by Institutions | 103.6% | 59.4% |
Scores
| Measure | Amylyx Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 66.56 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Amylyx Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.